| Literature DB >> 1777160 |
P Kaleebu1, R Cheingsong-Popov, D Callow, E Katabira, F Mubiru, B Biryahwaho, S Sempala, C Gilks, R Brindle, J B Were.
Abstract
We compared 1616 sera from HIV-1-infected subjects and matched HIV-negative local controls in Uganda, Kenya and the UK. Sera were screened for specific antibody to HIV-1 p24 Gag and gp120 Env proteins and for p24 antigenaemia. In contrast to the UK, the majority of African HIV-1-infected subjects maintained detectable anti-p24 antibodies. However, lower reactivity of anti-p24 was observed in African AIDS patients, compared with those with asymptomatic HIV-1 infection. This reduction in anti-p24 reactivity with more advanced clinical stage was less marked in African HIV-1 infection than in the UK. Correspondingly, p24 antigenaemia was more common in patients with AIDS from the UK than in African patients (65 versus 4%). Reductions in anti-gp120 reactivity were observed in African AIDS patients, compared with the asymptomatic group. However, median reactivity of anti-gp120 in UK patients remained unchanged in both asymptomatic and AIDS subjects. The differences in humoral response to p24 and gp120 between Africa and the UK are semi-quantitative rather than qualitative and could be explained by initial higher antibody response to HIV-1 in African subjects.Entities:
Keywords: Acquired Immunodeficiency Syndrome; Africa; Africa South Of The Sahara; Antibodies--changes; Biology; Case Control Studies; Comparative Studies; Developed Countries; Developing Countries; Diseases; Eastern Africa; English Speaking Africa; Europe; Examinations And Diagnoses; Hiv Infections; Immunity; Immunologic Factors; Kenya; Laboratory Examinations And Diagnoses; Northern Europe; Physiology; Research Methodology; Studies; United Kingdom; Viral Diseases
Mesh:
Substances:
Year: 1991 PMID: 1777160 DOI: 10.1097/00002030-199108000-00014
Source DB: PubMed Journal: AIDS ISSN: 0269-9370 Impact factor: 4.177